Ownership and insider activity for Anavex Life Sciences Corp. (AVXL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome.
Price
| Price | $2.36 |
| Market Cap | $219M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.2M | $27.4M | $22.9M | $22.2M | $29.2M | $152.1M | $149.2M | $151.0M | $132.2M | $102.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $79347 | $9748 | $1.9M | $2.6M | $4.8M | $9.1M | $3.2M | $2.7M | $2.4M | $809000 |
| Inventory | 0 | 0 | 0 | -$2.6M | 0 | $16365 | 0 | 0 | 0 | 0 |
| Total Current Assets | $9.4M | $27.8M | $24.3M | $25.3M | $34.5M | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $9.5M | $27.8M | $24.4M | $25.3M | $34.5M | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M |
| Accounts Payable | $3.1M | $3.6M | $3.0M | $3.5M | $4.0M | $4.7M | $3.8M | $4.3M | $9.6M | $4.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.2M | $3.6M | $3.9M | $5.0M | $7.3M | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $3.2M | $3.6M | $3.9M | $5.0M | $7.3M | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M |
| Retained Earnings | -$78.0M | -$91.5M | -$108.9M | -$133.4M | -$159.7M | -$197.6M | -$245.6M | -$293.1M | -$336.1M | -$382.4M |
| Total Equity | $6.3M | $24.3M | $20.5M | $20.3M | $27.2M | $150.8M | $142.5M | $141.9M | $120.3M | $94.9M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$9.2M | -$27.4M | -$22.9M | -$22.2M | -$29.2M | -$152.1M | -$149.2M | -$151.0M | -$132.2M | -$102.6M |
| Working Capital | $6.3M | $24.2M | $20.4M | $20.3M | $27.2M | $150.8M | $142.5M | $141.9M | $120.3M | $94.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 15.62 |
Profitability
| Return on Equity | -21.11% |
| Return on Invested Capital | -27.25% |
| Return on Assets | -20.01% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABSI · ARVN · ATXS · CTMX · ERAS · MBX · MGTX
Explore sector: Healthcare · Biotechnology
More sections of AVXL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks